Go Pro

Agilon Health (NYSE:AGL) Shares Climb 4.4% - Still a Buy?

Agilon Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Agilon Health shares rose 4.4% to about $79.17 in midday trading, though volume was 96% below the average daily level.
  • Analyst sentiment remains mixed: Bernstein and Benchmark upgraded the stock, while JPMorgan maintained an underweight rating. The overall consensus is “Hold”, with a $102.25 average price target.
  • The company beat quarterly expectations, reporting $1.04 in adjusted earnings per share versus a $0.14 consensus estimate and $1.49 billion in revenue. However, analysts expect a full-year loss, and Agilon continues to report negative profitability metrics.
  • Five stocks to consider instead of Agilon Health.

Agilon Health, Inc. (NYSE:AGL - Get Free Report)'s share price traded up 4.4% during mid-day trading on Friday. The stock traded as high as $78.24 and last traded at $79.1680. Approximately 15,002 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 335,667 shares. The stock had previously closed at $75.83.

Analyst Ratings Changes

AGL has been the topic of a number of recent research reports. Sanford C. Bernstein upgraded Agilon Health from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $86.00 to $125.00 in a report on Tuesday, September 15th. Citigroup upgraded Agilon Health from a "sell" rating to a "neutral" rating and increased their price target for the company from $105.00 to $115.00 in a research report on Monday, August 10th. Robert W. Baird set a $116.00 price target on Agilon Health in a research note on Thursday, August 6th. Benchmark restated a "buy" rating and set a $140.00 price objective (up from $95.00) on shares of Agilon Health in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Agilon Health from $31.00 to $85.00 and gave the company an "underweight" rating in a research note on Monday, August 24th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $102.25.

View Our Latest Stock Analysis on Agilon Health

Agilon Health Stock Performance

The firm has a 50 day moving average of $94.72 and a 200-day moving average of $74.10. The stock has a market capitalization of $1.41 billion, a PE ratio of -5.86 and a beta of 3.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.08 and a current ratio of 1.08.

Agilon Health (NYSE:AGL - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.90. The company had revenue of $1.49 billion for the quarter, compared to analysts' expectations of $1.45 billion. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%. Research analysts forecast that Agilon Health, Inc. will post -2.9 earnings per share for the current year.

Institutional Trading of Agilon Health

Several hedge funds and other institutional investors have recently modified their holdings of AGL. Rubicon Founders LLC bought a new stake in shares of Agilon Health in the 2nd quarter valued at approximately $11,290,448. Tidal Investments LLC acquired a new stake in Agilon Health in the second quarter valued at approximately $1,405,000. State Street Corp acquired a new stake in Agilon Health in the second quarter valued at approximately $30,024,000. Great Lakes Advisors LLC bought a new stake in Agilon Health in the second quarter worth approximately $702,000. Finally, Alpine Global Management LLC bought a new stake in Agilon Health in the fourth quarter worth approximately $84,000.

About Agilon Health

(Get Free Report)

Agilon Health, Inc is a healthcare company that partners with independent primary care physicians to support the transition from fee-for-service medicine to value-based care. The company focuses primarily on patients enrolled in Medicare Advantage plans and works with physician groups to coordinate care, improve outcomes and manage healthcare costs.

Agilon provides physicians with technology, analytics, operational support and clinical resources designed to help them manage the health of defined patient populations.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Agilon Health Right Now?

Before you consider Agilon Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilon Health wasn't on the list.

While Agilon Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own - Fall 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines